KCG Holdings Inc. decreased its position in shares of VIVUS, Inc. (NASDAQ:VVUS) by 18.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 117,169 shares of the biopharmaceutical company’s stock after selling 25,717 shares during the period. KCG Holdings Inc.’s holdings in VIVUS were worth $131,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Nine Chapters Capital Management LLC purchased a new position in shares of VIVUS during the first quarter worth about $113,000. Bank of New York Mellon Corp boosted its position in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 3,694 shares in the last quarter. Oxford Asset Management boosted its position in shares of VIVUS by 76.6% in the first quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock worth $658,000 after buying an additional 254,912 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of VIVUS by 164.7% in the first quarter. Acadian Asset Management LLC now owns 1,075,430 shares of the biopharmaceutical company’s stock worth $1,205,000 after buying an additional 669,165 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of VIVUS by 41.2% in the first quarter. Renaissance Technologies LLC now owns 6,182,454 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 1,805,100 shares in the last quarter. Hedge funds and other institutional investors own 35.47% of the company’s stock.

Shares of VIVUS, Inc. (NASDAQ VVUS) traded up 0.99% on Wednesday, reaching $1.02. 112,544 shares of the company were exchanged. The company’s 50-day moving average price is $1.20 and its 200 day moving average price is $1.12. VIVUS, Inc. has a 12 month low of $0.99 and a 12 month high of $1.47. The company has a market cap of $107.80 million, a price-to-earnings ratio of 3.09 and a beta of 0.86.

ILLEGAL ACTIVITY WARNING: “KCG Holdings Inc. Has $131,000 Position in VIVUS, Inc. (VVUS)” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/kcg-holdings-inc-has-131000-position-in-vivus-inc-vvus.html.

Separately, Zacks Investment Research cut shares of VIVUS from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VIVUS, Inc. (NASDAQ:VVUS).

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.